Sapirstein James's most recent trade in ZyVersa Therapeutics Inc was a trade of 11,066 Stock Options done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ZyVersa Therapeutics Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 11,066 | 11,066 | - | - | Stock Options | |
| Onconetix Inc | James Sapirstein | Director | 26 Sep 2024 | 3,318 | 3,477 | - | 0 | Common Stock | ||
| Entero Therapeutics Inc. | James Sapirstein | Director, Chairman and CEO | 02 Jul 2024 | 1,289 | 35,816 (0%) | 0% | 1.1 | 1,379 | Common Stock | |
| Renovaro Biosciences Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 48,137 | 48,137 | - | - | Option to purchase shares of common stock | |
| First Wave BioPharma Inc | James Sapirstein | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 4.23 per share. | 01 Apr 2024 | 174 | 37,105 (0%) | 0% | 4.2 | 736 | Common Stock |
| First Wave BioPharma Inc | James Sapirstein | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 4.96 per share. | 15 Mar 2024 | 1,887 | 37,279 (0%) | 0% | 5.0 | 9,360 | Common Stock |
| Renovaro Biosciences Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 28,196 | 28,196 | - | - | Option to Purchase Common Stock | |
| First Wave BioPharma Inc | Sapirstein James | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 12 Jan 2024 | 166 | 39,166 (0%) | 0% | 4.2 | 697 | Common Stock |
| First Wave BioPharma Inc | Sapirstein James | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 20,000 | 39,332 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | Sapirstein James | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 17,660 | 19,332 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | James Sapirstein | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.54 per share. | 03 Jul 2023 | 3,349 | 36,161 (0%) | 0% | 1.5 | 5,157 | Common Stock |
| Blue Water Biotech Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 6,360 | 6,360 | - | 0 | Common Stock | |
| ZyVersa Therapeutics Inc | Sapirstein James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 132 | 132 | - | - | Stock Options | |
| First Wave BioPharma Inc | James Sapirstein | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 03 Apr 2023 | 3,347 | 39,510 (0%) | 0% | 2.5 | 8,368 | Common Stock |
| Renovaro Biosciences Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 64,655 | 64,655 | - | - | Option to Purchase Common Stock | |
| First Wave BioPharma Inc | James Sapirstein | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 300,000 | 300,000 (1%) | 1% | 0 | Common Stock | |
| Blue Water Biotech Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 50,575 | 50,575 | - | - | Stock Option | |
| First Wave BioPharma Inc | James Sapirstein | Director, PRES, CEO & CHAIRMAN OF BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 150,000 | 150,000 | - | - | Stock option (right to buy) | |
| First Wave BioPharma Inc | James Sapirstein | Director, PRES, CEO & CHAIRMAN OF BOARD | Other type of transaction at price $ 0.00 per share. | 30 Jun 2021 | 900,000 | 300,000 | - | - | Stock options (right to buy) | |
| First Wave BioPharma Inc | James Sapirstein | Director, PRES, CEO & CHAIRMAN OF BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 900,000 | 900,000 | - | - | Stock options (right to buy) | |
| Renovaro Biosciences Inc | James Sapirstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2021 | 19,894 | 19,894 | - | - | Option to Purchase Common Stock |